New Study Shows Patients More Willing to Consider Self-Injectable HIV Therapy Than Many Physicians Anticipate

Dublin, Ireland, November 18 (ots/PRNewswire) -

- Latest Advances in Health Psychology may Help PhysiciansImplement Improved HIV Care

- News From 10th European AIDS Conference, Dublin, Ireland

Initial results from the OpenMind study, the largest behaviouralstudy to look at both patients' and physicians' perceptions of HIVcare in treatment-experienced patients, were revealed today at EACS.The study's findings are anticipated to help physicians implementimproved care to HIV patients and help pave the way for betteracceptance and integration of other new innovative drugs such asmonoclonal antibodies that are increasingly being developed for themanagement of HIV and other diseases.

The study was conceived to look at attitudes to FUZEON(enfuvirtide), the first approved HIV fusion inhibitor, and animportant option for treatment-experienced patients who face HIVresistance. FUZEON presents unique challenges because it is the firstself-injectable antiretroviral whereas all other treatments are oral.

Highlights from today's data show that:

- Patients are more willing to consider and use self-injectabletherapy than many physicians anticipate

- Three-quarters (76%) of patients would consider using aself-injectable HIV therapy if their physician recommended it

- Worryingly, only one quarter (28%) of patients who arepotentially eligible for FUZEON had actually discussed thisinjectable option with their physicians

- Only 10% of eligible patients were currently prescribed FUZEON,despite the fact that it is recommended in key international HIVtreatment guidelines

This study also identifies some of the main reasons why manyphysicians may be reluctant to prescribe a treatment of provenefficacy and safety. The reasons include; the physicians' perceptionthat patients would be reluctant to use a self-injectable therapy,the physicians' opinion that the patient would not be able toincorporate FUZEON into their lifestyle and the potentialmisconception that FUZEON is not appropriately recommended inguidelines.

"Physicians' best intentions in trying to match treatments topatients may actually be limiting the use of FUZEON in those patientswho are most likely to benefit," said Rob Horne, Professor ofPsychology at the University of Brighton and OpenMind study author.

"These new insights from the OpenMind study will enable us todevelop tools to facilitate more informed decisions by both patientand physician."

The study also shows that physicians' own experiences andattitudes towards self-injection are a significant motivator for itsuse. Physicians with considerable FUZEON experience weresignificantly more likely to justify using self-injectable therapy interms of time and resources and were less likely to doubt itsefficacy relative to oral therapies, when compared to physicians lessexperienced with this type of treatment.

Dr Mike Youle, Director of HIV Clinical Research, Royal FreeHospital, London and co-author of the OpenMind study stated, "Withthe increasing choice of injectable biotech drugs includingmonoclonal antibodies, these findings potentially have far reachingimplications across a whole range of therapeutic areas. We lookforward to presenting the final results and exploring possibleinterventions at major congresses next year."

Notes to Editor:

The OpenMind study was designed by Professor Rob Horne incollaboration with Roche and reviewed by a panel of HIV treatingphysicians and community representatives. Data collection wasundertaken by an independent agency and all interviews were conductedin accordance with the Data Protection Act and the MRS Code ofConduct by trained medical interviewers. Data analysis wasindependently conducted under the supervision of Professor Rob Horneand supported by an unrestricted educational grant from Roche.

This study was designed to identify the drivers and barriers touse of injectable antiretrovirals from the perspective of bothpatients and physicians. The findings will inform the design ofevidence-based interventions to optimise HIV care through greaterconcordance between physician and patient perspectives. The resultshave been collated from 499 physician and 603 treatment-experiencedpatient interviews, from across six countries (France, Germany,Italy, Spain, UK and USA).

Patients were at least 16 years old, taking antiretroviral therapyand were treatment-experienced (patients who had been exposed to, butwho had not necessarily failed therapy with, at least eight differentantiretrovirals including those in their current regimen). Physicianswere HIV or infectious disease specialists treating HIV patients andwith at least three years of experience prescribing antiretroviraltherapy. At least 15% of patients in their clinic were estimated tobe treatment-experienced.

Copies of the two posters presented at EACS are available uponrequest from Kate Pogson at Ketchum - kate.pogson@ketchum.com/ +44(0) 7941 418962

- Poster PE7.3/24 - Potential barriers and motivators toenfuvirtide use: Physician and patient perspectives of injectableantiretrovirals (ARVs). Youle M et al (UK)

- Poster PE7.3/25 - Treatment-experienced patient perceptions ofself-injectable therapy. Horne R et al (UK)

ots Originaltext: Roche PharmaceuticalsIm Internet recherchierbar: http://www.presseportal.de

Contact:For more information, please contact: Peter Impey, Ketchum, Mobile: +44-(0)-7976-734493, Peter.impey@ketchum.com. Professor Rob Horne, Professor of Psychology in Health Care and Director, Centre for Health Care Research, University of Brighton, Tel: + 44-(0)-1273-643985, r.horne@bton.ac.uk

Roche Pharmaceuticals

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


New Study Shows Patients More Willing to Consider Self-Injectable HIV Therapy Than Many Physicians Anticipate